Soligenix, Inc. — 2019 Form 10-K
Business context and reporting period. This filing covers the fiscal year ended December 31, 2019, not a standalone fourth quarter. Soligenix is a clinical-stage biopharmaceutical company with Specialized BioTherapeutics and Public Health Solutions segments. It had no approved products and generated no significant product-sales revenue; revenue was primarily from government contracts and grants.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $4.63 million | $5.24 million |
| Gross profit / margin | $1.06 million / 23% | $0.64 million / 12% |
| Research and development | $8.12 million | $6.75 million |
| General and administrative | $3.48 million | $2.95 million |
| Operating loss | $10.54 million | $9.06 million |
| Net loss | $9.36 million | $8.90 million |
| Cash used in operating activities | $7.51 million | $7.24 million |
| Cash and cash equivalents at year-end | $5.42 million | $8.98 million |
| Working capital at year-end | $1.18 million | $6.13 million |
Revenue declined 12%, largely as government-funded work and grants wound down. Gross profit improved principally because of milestones under the RiVax contract. Higher SGX942 and SGX301 clinical-trial spending contributed to the 5% increase in net loss. Other income included $433,594 of UK research and development incentives; the company also recognized a $610,676 New Jersey tax benefit from selling prior-year net operating losses.
Financing activities provided $4.01 million in 2019, primarily from at-the-market stock sales. Soligenix issued approximately 3.82 million shares under its FBR sales agreement, raising $4.14 million before related costs. The balance sheet reported $6.32 million of total liabilities, chiefly accounts payable, accrued expenses and lease liabilities; no conventional borrowings are identified in the provided financial statements. Accumulated deficit was $175.53 million and shareholders’ equity was $1.46 million.
Management said cash, expected government contract and grant proceeds, and remaining FBR sales capacity were expected to fund operations for at least 12 months from issuance of the financial statements. The filing also cites an expected operating runway through at least March 31, 2021, based on projected needs and funding assumptions. This outlook depends on continued funding, equity sales and spending plans; additional financing may be needed.
Material developments and outlook
- SGX301 (CTCL): The pivotal Phase 3 primary-endpoint analysis was reported statistically significant in March 2020, after the fiscal year-end. The company reported response rates of 16% for SGX301 versus 4% for placebo at eight weeks. It planned to pursue an NDA and explore partnering and commercialization. In March 2020, it issued 1,956,182 shares to Hy Biopharma for a trial-success milestone.
- SGX942 (oral mucositis): The Phase 3 trial received a positive interim-monitoring recommendation in August 2019, with no safety concerns reported. Final top-line results were expected in the fourth quarter of 2020. The timing and outcome remain uncertain.
- RiVax/ThermoVax: A Phase 1c study began in December 2019 and was suspended in January 2020 after the drug-substance manufacturer reported the active substance was outside established specifications. Two participants had been dosed and were to be monitored; no further doses were planned. The company reported that up to $2.97 million in awarded contract and grant funding remained available at year-end, subject to government options and termination rights.
- Other pipeline: Phase 3 development of SGX203 and further development of SGX201 were contingent on additional funding. SGX943 remained preclinical. On March 11, 2020, Soligenix and a collaborator expanded research work to potential coronavirus vaccines, including SARS-CoV-2; this was a research collaboration, not evidence of a vaccine candidate’s efficacy.
- COVID-19 and execution risks: The filing warned that the outbreak could disrupt materials supply, manufacturing, patient availability, clinical operations and regulatory timelines. Soligenix relies on third parties for manufacturing and clinical work, and noted that drug substances were supplied by single suppliers.
- Further post-year-end financing and dilution: From January 1 through March 23, 2020, the company sold 1,732,115 shares under its FBR agreement at a weighted-average $2.30 per share, and issued 304,615 shares upon warrant exercises. It reported approximately $0.9 million of remaining FBR capacity as of March 23, 2020.
Key investor verification points
- Confirm the full SGX301 Phase 3 results, follow-up outcomes, regulatory filing plans and implications of the 1,956,182-share milestone issuance.
- Track SGX942 Phase 3 enrollment, final results and whether the anticipated timing or development costs change.
- Determine whether RiVax’s manufacturing-specification issue was resolved, whether the suspended study produced a safety report, and whether further trials can proceed.
- Reassess cash burn, working capital, remaining grant availability, ATM capacity and the need for additional financing; monitor resulting shareholder dilution.
- Check whether government agencies exercise contract options and whether COVID-19 or single-supplier dependence affects trial, manufacturing or regulatory timelines.
- Review the collectability and timing of the $444,043 UK R&D incentive receivable and the availability of New Jersey tax-credit proceeds; the filing says the relevant 2018 benefit had not yet been recognized pending receipt of the certificate.